Hypertrophic perianal herpes successfully treated with imiquimod

Herpes hipertrófico perianal tratado eficazmente com imiquimod

Sara Isabel Alcântara Lestre
Alexandre João
Célia Carvalho
Vasco Vieira Serrão

Abstract: Herpes simplex virus type 2 (HSV-2) infections are frequent in HIV (human immunodeficiency virus) infected patients. In those cases, genital herpes may have an atypical clinical presentation. Hypertrophic and vegetating variants are unusual. The authors describe a case of hypertrophic perianal herpes in an HIV patient with unsatisfactory response to acyclovir and valacyclovir, successfully treated with imiquimod. Hypertrophic genital herpes cases are frequently refractory to antiviral treatments. In our experience, imiquimod is an efficient, safe and well tolerated treatment that should be considered in therapeutic approach of these patients.

Keywords: Antiviral agents; Combined modality therapy; Efficacy; Herpes genitalis; Herpesvirus 2, human

INTRODUCTION

Herpes simplex virus (HSV) infections are the main cause of genital ulcers worldwide, and HSV-2 is the serotype most frequently implicated in its etiology. The synergism between the HSV-2 and the human immunodeficiency virus (HIV) infections has been demonstrated in several epidemiological and clinical studies, with increased frequency in reactivation of HSV-2 in HIV-positive individuals. On the other hand, HSV-2 infection increases the risk of acquiring HIV and hastens disease progression. The ulcerative form is the most frequent clinical presentation of genital herpes, detected by the presence of small grouped vesicles that result in painful superficial ulcers, often accompanied by inguinal lymphadenopathies. In individuals coinfected by VIH, the clinical aspects are frequently atypical and extensive ulcers may be observed, which tend to be chronic, many times with bacterial suprainfection. More rarely, pseudo-tumoral hypertrophic forms that simulate squamous cell carcinoma or other viral infections have been described. In these cases, a high degree of clinical suspicion is required. The synergism between the HSV and HIV infections is also reflected in the therapeutic approach to genital herpes, particularly in individuals with low lymphocyte T CD4+ counts. In these patients, systemic antivirals are used in higher doses and for longer periods, and there is a higher prevalence rate of cases that are resistant to acyclovir. The onset of hypertrophic genital herpes usually occurs in the immunodepression context and it is often resistant to antiviral therapies, with frequent relapses. The authors report a case of hypertrophic perianal genital herpes...
in HIV-positive patient, where the utilization of topical imiquimod was found to be effective.

**CASE REPORT**

A 49-year-old female patient, black, from Guinea-Bissau, resident in Portugal (Lisbon) for eight years, was referred for a dermatology appointment in February 2010 with a painful vegetating tumor located in the left perianal region for two months, with progressive worsening.

This was a patient that had received HIV-1 infection diagnosis six months before. She had begun treatment with tenofovir/emtricitabine and nevirapine 1 month before (January 2010) due to low lymphocyte T CD4+ count (197/mm$^3$) and viral load of 32000 HIV/RNA copies per milliliter. There was no prior history of sexually transmissible or opportunistic infections.

Medical observation revealed a rounded, well-defined tumor with 4 cm diameter, located in the left perianal region (Figure 1). No other relevant alterations were detected in the physical examination. Considering the clinical context, diagnostic hypotheses of hyperthrophic perianal genital herpes, squamous cell carcinoma and genital condyloma were equated. An incisional cutaneous biopsy showed epidermal hyperplasia, multinucleate epithelial cells, focal ballooning epidermal degenerescence and dense mixed dermal inflammatory infiltrate (Figure 2). Lesion investigation was also carried out by polymerase chain reaction (PCR) for HSV-1, HSV-2 and human papilloma virus (HPV), where only HSV-2 positivity was detected. The investigation of mycobacteria and deep fungi was also negative. The laboratory evaluation highlighted positivity for IgG HSV-2, while IgM HSV-2 was negative. The hemogram and biochemical tests were normal. Other active infections were excluded, mainly viral hepatites, infection by cytomegalovirus (CMV), Epstein-Barr virus (EBV) and syphilis. Therapy with acyclovir at the maximum dose (800 mg 4/4h) was started, with good initial clinical response that resulted in visible decrease in lesion dimensions (Figure 3). However, as of the second month of treatment a loss of response was observed. Acyclovir was replaced by valacyclovir 1 g 12/12 hours during one month, with no satisfactory clinical improvement. As of the 4th month of treatment, topical imiquimod was associated with valacyclovir. Imiquimod was applied with occlusion, three times a week during the first two weeks and then on five consecutive days per week. The treatment was well tolerated by the patient, without any local and/or systemic significant adverse effect. The clinical response was excellent, which was particularly evident after the increase in frequency of application, with complete remission after 10 weeks of treatment (Figure 4).

After the clinical remission of the perianal lesion, the valacyclovir dose was reduced to 1g/day. At two months of follow-up, the patient continues clinically stable, with no signs of relapse, lymphocyte count CD4+ 310/mm$^3$ and viral load lower than 20 HIV/RNA copies per milliliter.

**DISCUSSION**

In patients with HIV infection, the presence of anogenital vegetating lesions is common, possibly the infection or carcinoma clinical presentation form. HPV infection is the most frequent of anogenital verrucous lesions; however, infections caused by the Varicella-Zoster Virus, CMV, Molluscum Contagiosum and HSV should be considered in the differential diagnosis. The hypertrophic variant of genital herpes is rare and has been described in the context of immuno- depression, particularly in patients with HIV infection and/or immune reconstitution inflammatory syndrome (IRIS). The reason why this hypertrophic

![Figure 1: A. Tumor with well-defined limits in the left perianal region; B. Detail of tumoral lesion on plane, ulcerated and friable surface](An Bras Dermatol. 2011;86(6):1185-8.)
variant appears almost exclusively in patients coinfected by HIV is not totally clear, since there seems to be no correlation with the degree of immunodepression and/or lymphocyte count T CD4+. Nevertheless, the evolution into hypertrophic forms of genital herpes may be partially justified by immunological deregulation secondary to HIV infection, particularly by: 1) Production of TNF-alpha by an increased number of plasmacytoid dendritic cells factor XIII-positive, promoting the keratinocyte growth rate and consequent acanthosis and hyperkeratosis and 2) Diminution of IFN-gamma production, a cytokine that plays an important regulating role in keratinocyte activity.

In this case, the clinical evolution of HSV-2 infection does not seem to be related to the patient’s immunodepression degree, as the antiretroviral therapy (ART) was started after the lesion onset, excluding the hypothesis of IRIS. On the other hand, the initial progression of the perianal tumor was not interrupted by immunological recuperation induced by ART.

This variant is clinically defined by the presence of exophytic and painful tumors, with well-defined limits and ulcerated surface, located on the perianal region, vulva, penis and scrotum. However, similar lesions have also been described in extragenital locations. The diagnosis is based on correlation between the clinical and histological data, supported by HSV isolation and exclusion of other infectious causes. Histologically, variable epidermal hyperplasia can be observed, with multinucleate epithelial cells and dense mixed dermal inflammatory infiltrate composed of lymphocytes, plasmocytes and eosinophils. It is recommended to perform an incisional cutaneous biopsy, since small samples may be insufficient for diagnosis and masked by the intense inflammatory response to the virus. The demonstration of the lesional HSV presence may be done through immunohistochemical methods or PCR.

The hypertrophic genital herpes is often refractory to first-line systemic antiviral agents, like acyclovir (oral and intravenous), valacyclovir and famciclovir. In such cases, foscarnet, interferon-beta and cidofovir have been used, despite variable effectiveness outcomes. Another therapeutic alternative to be considered is thalidomide, recently described by Holmes et al. Finally, surgical excision may be considered in small tumors.

Imiquimod is a topical immunomodulator with antitumoral and antiviral activity, inducing synthesis and liberation of several endogenous proinflammatory cytokines TH-1, namely interferon-alpha. Although there are no randomized studies, the efficacy of topical imiquimod in the treatment of chronic genital herpes in immunodepressed individuals has been described in the literature. In cases of genital herpes particularly resistant to medical therapies, such as the hypertrophic variant, the role of imiquimod is still not clear. Recently, it was used in the treatment of hypertrophic genital lesions caused by HSV-2 in two HIV-positive patients resistant to conventional medical treatments (oral acyclovir, intravenous acyclovir, valacyclovir and foscarnet). The first case was reported in 2007 and described a male patient with severe immunosuppression and vegetating lesions located on the penis and scrotum. In 2008, Yudin and Kaul reported the second case in a female patient with persistent hypertrophic vulvar lesions after starting anti-
retrorviral therapy (ART) and full immunological re- 

cuperation. In both patients, the application of imiqui-
mod three times a week was associated with systemic 
antiviral therapy (famcyclovir 500 mg twice a day and 
valacyclovir 1 g twice a day, respectively), resulting in 
complete lesion remission after 2 to 8 weeks of treat-
ment. In the present case, we also observed excellent 
response to imiquimod, with full regression of the 
lesion after 10 weeks of treatment. As previously sug-
gested by Bangsgaard and Skov, we verified that the 
increased number of weekly applications seems to be 
associated with faster response. In the case above 
described, we chose to apply imiquimod with occlu-
sion to para potentiate the efficacy of the treatment, 
which could be limited by the lesion location and size. 
This form of application is frequently badly tolerated, 
however, in our patient no significant local and/or sys-

temic adverse effects were observed.

Hypertrophic genital herpes is a rare variant of 
genital herpes that should be equated in the presence 
of anogenital vegetating lesions in patients with HIV 
coinfection. Imiquimod should be considered in the 
therapeutic approach to these patients, as it is an 
effective, safe and well-tolerated treatment.

REFERENCES


of sexually transmitted diseases. Part III. Sexually transmitted diseases in HIV-
4. Samarutunga H, Weedon D, Musgrave N, McCullum N. Atypical presentation of 
herpes simplex (chronic hypertrophic herpes) in a patient with HIV infection. 
Pathology. 2001;33:532-5.

MAILING ADDRESS / ENDEREÇO PARA CORRESPONDÊNCIA:
Sara Isabel Alcântara Lestre
Serviço de Dermatologia
Hospital de Santo António dos Capuchos
Alameda Santo António dos Capuchos
1150 - 314 Lisboa
E-mail: saralestre@gmail.com

How to cite this article/Como citar este artigo: Lestre SIA, João A, Carvalho C, Serrão VV. Hypertrophic perianal herpes successfully treated with imiquimod. An Bras Dermatol. 2011;86(6):1185-8.